The implementation of early respiratory syncytial virus (RSV) infection prevention with the long-acting monoclonal antibody nirsevimab during the 2023–24 cold season marked a major turning point for infants and for health-care systems as a whole.1 In countries where nirsevimab was introduced in the northern hemisphere, the first season of its use was associated with a striking reduction in RSV bronchiolitis, in both hospital and ambulatory settings.1,2 Notably, although RSV-A was predominant during the 2023–24 season, whereas RSV-B was predominant during the 2024–25 season, the effectiveness of nirsevimab was nevertheless confirmed for both seasons, both for bronchiolitis cases requiring hospitalisation and for those managed in the community.
The Lancet Infectious Diseases published a clinical update in Infectious Disease on 12 Jan 2026. The item focuses on Nirsevimab over two RSV seasons: do the findings align with expectations?. Open the detail page to review the full original feed content.